Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Lafayette

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Lancet (London, England)|November 6, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, et al.
Kidney International Reports|December 18, 2023
Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA NephropathyFrederick W K Tam, James Tumlin, Jonathan Barratt, et al.
JAMA Network Open|August 25, 2022
Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental GlomerulosclerosisDebbie S Gipson, Jonathan P Troost, Cathie Spino, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 27, 2021
Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney FoundationAndrew S Bomback, Gerald B Appel, Debbie S Gipson, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Lancet (London, England)|November 6, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, et al.
Kidney International Reports|December 18, 2023
Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA NephropathyFrederick W K Tam, James Tumlin, Jonathan Barratt, et al.
JAMA Network Open|August 25, 2022
Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental GlomerulosclerosisDebbie S Gipson, Jonathan P Troost, Cathie Spino, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 27, 2021
Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney FoundationAndrew S Bomback, Gerald B Appel, Debbie S Gipson, et al.
Pageof 5